Abstract
Rapid development of an updated mRNA vaccine against the SARS-CoV-2 Omicron variant
Highlights
The newest SARS-CoV-2 variants of concerns (VOC), Omicron designated by WHO was first reported in South Africa in November 2021
We took an immediate action to start the effort of developing an Omicron mRNA vaccine based on our established Lipid nanoparticle (LNP)-mRNA vaccine platform
The most potent two mRNA constructs, named Omicron/1 and Omicron/2, were selected from a total of 18 mRNAs with different untranslated regions (UTRs) and codon optimizations based on their in vitro expression levels detected by enzyme linked immunosorbent assay (ELISA) (Supplementary information, Fig. S1)
Summary
The newest SARS-CoV-2 VOC, Omicron ( known as B.1.1.529) designated by WHO was first reported in South Africa in November 2021. A third dose of mRNA vaccination (booster) has been widely used and well evidenced to induce more robust antibody response and improve vaccine efficacy against VOCs.[11,12,13] To make sure the potential impact of a homologous booster of ARCoV, groups of 8–9-month female BALB/c mice that have received two doses of ARCoV were further boosted with a third dose ARCoV at day 300 post prime immunization (Fig. 1c). A booster immunization readily induced the production of neutralization antibody, and the GMTs against WT and Omicron increased to 28387.66 and 17206.32, respectively.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
